目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) - Overview
Premature Labor (Tocolysis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
Premature Labor (Tocolysis) - Drug Profiles
ebopiprant - Drug Profile
Product Description
Mechanism Of Action
History of Events
EG-003 - Drug Profile
Product Description
Mechanism Of Action
GXP-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
hydroxyprogesterone caproate - Drug Profile
Product Description
Mechanism Of Action
History of Events
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
History of Events
progesterone 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Protein for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
retosiban - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
VMSC-0204 - Drug Profile
Product Description
Mechanism Of Action
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Jul 02, 2021: ObsEva to present Ebopiprant (OBE022) data at the Society for Reproductive Investigation 68th Annual Meeting
Jun 10, 2021: ObsEva presents prolong phase 2a proof-of-concept data on Ebopiprant (OBE022) for the treatment of spontaneous preterm labor at the RCOG Virtual World Congress 2021
Jun 02, 2021: ObsEva announces oral presentation at the RCOG Virtual World Congress 2021
Nov 16, 2020: ObsEva reports positive topline results of the prolong proof-of-concept trial of Ebopiprant (OBE022) for treatment of preterm labor
Aug 19, 2020: Dare Bioscience announces funding award notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to support DARE-FRT1 phase 1 human clinical study for the prevention of preterm birth
Jan 15, 2020: ObsEva to provide update on OBE022 at JP Morgan Healthcare Conference in San Francisco
Oct 10, 2019: Dare Bioscience announces a poster presentation on a pharmacokinetic study of DARE-FRT1, in development for sustained-release progesterone therapy for pregnancy maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
Jul 26, 2019: ObsEva reports positive feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
Mar 13, 2019: ObsEva to present OBE022 clinical data for treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
Jan 22, 2019: ObsEva SA reports initial good safety of OBE022 in pregnant women with preterm labour and announces start of part B of the PROLONG trial
Oct 30, 2018: Dare Bioscience to present preclinical data of DARE-FRT1 at AAPS 2018 meeting
Mar 01, 2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting
Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Premature Labor (Tocolysis) - Pipeline by Dare Bioscience Inc, 2022
Premature Labor (Tocolysis) - Pipeline by Egret Therapeutics Inc, 2022
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, 2022
Premature Labor (Tocolysis) - Pipeline by ILIAS Biologics Inc, 2022
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, 2022
Premature Labor (Tocolysis) - Pipeline by Organon & Co, 2022
Premature Labor (Tocolysis) - Pipeline by Osel Inc, 2022
Premature Labor (Tocolysis) - Pipeline by Seed Health Inc, 2022
Premature Labor (Tocolysis) - Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022
Premature Labor (Tocolysis) - Dormant Projects, 2022
Premature Labor (Tocolysis) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Premature Labor (Tocolysis), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022